Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has earned a consensus recommendation of “Moderate Buy” from the sixteen analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fourteen have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $199.5333.

PVLA has been the topic of several recent research reports. Chardan Capital reiterated a “buy” rating and set a $240.00 target price on shares of Palvella Therapeutics in a research report on Thursday, May 21st. BTIG Research boosted their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. Mizuho boosted their price target on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Finally, Truist Financial set a $210.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, February 24th.

Palvella Therapeutics Stock Performance

NASDAQ:PVLA opened at $112.63 on Thursday. Palvella Therapeutics has a 52 week low of $20.20 and a 52 week high of $151.18. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -27.01 and a beta of -0.15. The firm’s 50-day simple moving average is $118.97 and its 200 day simple moving average is $108.85.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Sell-side analysts anticipate that Palvella Therapeutics will post -5.26 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PVLA. KBC Group NV purchased a new stake in shares of Palvella Therapeutics in the first quarter valued at about $28,000. Group One Trading LLC raised its holdings in shares of Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Palvella Therapeutics in the third quarter valued at about $36,000. JPMorgan Chase & Co. raised its holdings in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after purchasing an additional 3,242 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Palvella Therapeutics in the second quarter valued at about $85,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.